乳腺癌放疗抵抗研究现状

doi:10.11904/j.issn.1002-3070.2025.03.013

摘要/Abstract

摘要： 乳腺癌作为一种常见的恶性肿瘤,是女性癌症死亡的主要原因,放疗(radiotherapy,RT)是其主要的治疗方法之一。放疗抵抗是指肿瘤细胞和组织对放疗的生物效应的抵抗,发生放疗抵抗与乳腺癌复发、转移及预后恶化密切相关。近年来,乳腺癌放疗抵抗已成为放疗研究领域的一个核心议题。本文旨在综述乳腺癌放疗抵抗的潜在机制、影响因素以及相应的应对措施,为临床实践中实施个性化精准医疗提供新的思路。

关键词: 乳腺癌, 放疗, 放疗抵抗

Abstract: As a common malignant tumor,breast cancer is the main cause of cancer death in women.Radiotherapy(RT)is one of its main treatment methods for breast cancer.RT resistance refers to the resistance of tumor cells and tissues to the biological effects of RT.The occurrence of RT resistance is closely related to the recurrence,metastasis and prognosis deterioration of breast cancer.In recent years,RT resistance of breast cancer has become a core issue in the field of RT research.The aim of this article is to review the potential mechanisms,influencing factors and corresponding countermeasures of breast cancer RT resistance,and to provide new ideas for the implementating personalized precision medicine in clinical practice.

Key words: Breast cancer, Radiotherapy, Radiotherapy resistance

中图分类号:

吴丹, 王义海. 乳腺癌放疗抵抗研究现状[J]. 实用肿瘤学杂志, 2025, 39(3): 262-266.

WU Dan, WANG Yihai. Current status of radiotherapy resistance research in breast cancer[J]. Journal of Practical Oncology, 2025, 39(3): 262-266.

参考文献

1 Brayf F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
2 Sun K,Zhang B,Lei S,et al.Incidence,mortality,and disability-adjusted life years of female breast cancer in China,2022[J].Chin Med J(Engl),2024,137(20):2429-2436.
3 纪璟,姜鹏,王汉晋.保乳手术在乳腺癌不同分子亚型患者中的临床疗效对比及其术后复发因素的分析[J].华南国防医学杂志,2020,34(9):626-630.
4 贺新,彭书甲,师弘.乳腺癌患者原发灶与复发转移灶中ER、PR、HER-2及Ki-67表达异质性的回顾性分析[J].现代肿瘤医学,2023,31(9):1660-1665.
5 张豪亭,杨银涛,马宇杰,等.细胞骨架相关蛋白4在肾透明细胞癌中的表达及其临床意义[J].中国癌症防治杂志,2023,15(2):190-195.
6 Wang X,Xing L,Yang R,et al.The circACTN4 interacts with FUBP1 to promote tumorigenesis and progression of breast cancer by regulating the expression of proto-oncogene MYC[J].Mol Cancer,2021,20(1):91.
7 Tentler D,Lomert E,Novitskaya K,et al.Role of ACTN4 in tumorigenesis,metastasis,and EMT[J].Cells,2019,8(11):1427.
8 张馨文,王波,许果.程序性死亡受体-配体1、E-钙黏蛋白、N-钙黏蛋白、信号转导及转录激活因子3表达与胸腺癌预后的关系研究[J].实用医院临床杂志,2022,19(4):51-56.
9 金梅,袁春雷,段思佳,等.趋化因子C-C-基元配体5对乳腺癌干细胞增殖和侵袭的影响研究[J].中国临床药理学杂志,2021,37(8):1000-1003.
10 向左娟,胡晓杰,陈小娟,等.基于生物信息学寻找乳腺癌干细胞上皮间充质转换的关键调节基因[J].湖南师范大学学报(医学版),2022,19(2):51-55.
11 Beck B,Blanpain C.Unravelling cancer stem cell potential[J].Nat Rev Cancer,2013,13(10):727-738.
12 Peng L,Zhang Z,Zhao D,et al.Discordance in ER,PR,HER2,and Ki-67 expression between primary and recurrent/metastatic lesions in patients with primary early stage breast cancer and the clinical significance:retrospective analysis of 75 cases[J].Pathol Oncol Res,2021,27:599894.
13 Kim Yg,Yoon Yn,Choi Hs,et al.Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion:clinical implications for serum HER2 in recurrent HER2-negative breast cancer[J].Oncotarget,2018,9(5):5811-5822.
14 Zhang L,Chen W,Liu S,et al.Targeting breast cancer stem cells[J].Int J Biol Sci,2023,19(2):552-570.
15 梁雪丽,廖海,苏丹柯.整合素在乳腺癌中应用的研究进展[J].医学综述,2022,28(6):1103-1107.
16 Ahmed Km,Pandita Rk,Singh Dk,et al.Beta1-integrin impacts Rad51 stability and DNA double-strand break repair by homologous recombination[J].Mol Cell Biol,2018,38(9):e00672-17.
17 毕月.乳腺癌放疗抵抗机制的研究进展[J].中国医学创新,2023,20(30):172-176.
18 Liu W,Zheng M,Zhang R,et al.RNF126-mediated MRE11 ubiquitination activates the DNA damage response and confers resistance of triple-negative breast cancer to radiotherapy[J].Adv Sci(Weinh),2023,10(5):e2203884.
19 Sriramulu S,Thoidingjam S,Chen W,et al.BUB1 regulates non-homologous end joining pathway to mediate radioresistance in triple-negative breast cancer[J].J Exp Clin Cancer Res,2024,43(1):163.
20 Zhang F,Zheng Z,Wang L,et al.PKC-zeta mediated reduction of the extracellular vesicles-associated TGF-beta1 overcomes radiotherapy resistance in breast cancer[J].Breast Cancer Res,2023,25(1):38.
21 Loi S,Michielss,Salgado R,et al.Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer:results from the FinHER trial[J].Ann Oncol,2014,25(8):1544-1550.
22 Kovacs A,Stenmark Tullberg A,Werner Ronnerman E,et al.Effect of radiotherapy after breast-conserving surgery depending on the presence of tumor-infiltrating lymphocytes:a long-term follow-up of the sweBCG91RT randomized trial[J].J Clin Oncol,2019,37(14):1179-1187.
23 Patwardhan Rs,Rai A,Sharma D,et al.Txnrd1 as a prognosticator for recurrence,metastasis and response to neoadjuvant chemotherapy and radiotherapy in breast cancer patients[J].Heliyon,2024,10(6):e27011.
24 Patwardhan RS,Sharma D,Sandur SK.Thioredoxin reductase:An emerging pharmacologic target for radiosensitization of cancer[J].Transl Oncol,2022,17:101341.
25 Pellizzari S,Bhat V,Athwal H,et al.PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer[J].Radiat Oncol,2024,19(1):24.
26 常添添,段伟.再程放疗与热疗联合治疗复发性乳腺癌研究进展[J].中国辐射卫生,2024,33(5):615-620.
27 Andratschke N,Willmann J,Appelt AL,et al.European society for radiotherapy and oncology and european organisation for research and treatment of cancer consensus on re-irradiation:definition,reporting,and clinical decision making[J].Lancet Oncol,2022,23(10):e469-e478.
28 Oldenborg S,Rasch Crn,van Os R,et al.Reirradiation + hyperthermia for recurrent breast cancer en cuirasse[J].Strahlenther Onkol,2018,194(3):206-214.
29 安迪.放疗联合热疗在乳腺癌肺转移患者中的应用效果[J].医疗装备,2023,36(10):52-55.
30 白诗婷,吴亚军,吴稚冰.全身热疗抗恶性肿瘤的研究进展[J].浙江临床医学,2024,26(2):293-296.
31 Chen M,Xiao L,Jia H,et al.Stereotactic ablative radiotherapy and FAPalpha-based cancer vaccine suppresses metastatic tumor growth in 4T1 mouse breast cancer[J].Radiother Oncol,2023,189:109946.
32 罗波,张曲,郑红梅,等.SRT联合拉帕替尼治疗HER2阳性乳腺癌脑转移疗效及预后分析[J].实用肿瘤学杂志,2021,35(6):523-528.
33 郑佳俊,翟振宇,孙丽.瓦里安高分辨率多叶准直器叶片位置误差对肺肿瘤立体定向放疗剂量学影响[J].中华放射肿瘤学杂志,2021,30(9):930-935.
34 夏铀铀,武丹,范育伟,等.基于放疗前增强定位CT的影像组学预测非小细胞肺癌脑转移分次立体定向放疗的近期疗效[J].实用肿瘤杂志,2022,37(5):465-469.
35 陈晓亮,王豪杰,王红旗.分次立体定向放疗联合全脑放疗治疗乳腺癌脑转移患者的临床疗效[J].癌症进展,2024,22(8):881-884.

[1]	王锐, 马得原, 贾王强, 关泉林. 纳米医学介导的铜死亡在乳腺癌治疗中的应用和进展[J]. 实用肿瘤学杂志, 2025, 39(2): 144-150.
[2]	王帅, 黎其庆, 李瑞, 许铁峰. 纳米粒子在乳腺癌诊断和治疗中的应用进展[J]. 实用肿瘤学杂志, 2025, 39(2): 151-156.
[3]	王铷, 张红霞. 磁共振成像技术在预测乳腺癌淋巴血管侵犯中的应用研究进展[J]. 实用肿瘤学杂志, 2025, 39(2): 162-168.
[4]	谷文, 周澜, 贾燕妮, 黄卫东. QLU-C10D量表在乳腺癌患者中测量属性的验证研究[J]. 实用肿瘤学杂志, 2025, 39(1): 49-55.
[5]	石长勇, 周紫珍, 周广林, 熊益敏. DCE-MRI定量参数联合NCAPH检测诊断早期乳腺癌的价值分析[J]. 实用肿瘤学杂志, 2025, 39(1): 56-60.
[6]	张宇晴, 荆晶, 刘兆良, 安静, 安巍巍. MZB1的可变剪接事件是乳腺癌内分泌治疗耐药的潜在生物标志物[J]. 实用肿瘤学杂志, 2024, 38(5): 313-322.
[7]	杨闽叶, 鲜童丞, 刘景建, 别俊, 王杰, 罗义. IL-23在乳腺癌组织中的表达及其与患者临床病理特征的相关性[J]. 实用肿瘤学杂志, 2024, 38(5): 323-329.
[8]	刘冬, 张太娟, 党计锋. 炎症反应驱动乳腺癌转移的研究进展[J]. 实用肿瘤学杂志, 2024, 38(5): 336-341.
[9]	李倩妮, 徐灵燕, 李健, 姚雪佩, 刘美娜. 乳腺癌多维治疗质量纵向评价的趋势分析[J]. 实用肿瘤学杂志, 2024, 38(4): 213-220.
[10]	高光强, 王发琳, 李娟, 田虹, 果思伽, 于晓兰, 杨婷婷, 刘家仁. β-紫罗兰酮通过NF-κB途径抑制乳腺癌细胞增殖[J]. 实用肿瘤学杂志, 2024, 38(4): 254-261.
[11]	邵禹铭, 朱坤兵, 张洁. SP/NK-1R系统在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(4): 268-272.
[12]	殷海燕, 淳志明, 马巧君, 成涵, 丁高恒, 张海燕, 刘玉琴. 2019年甘肃省肿瘤登记地区女性乳腺癌流行特征及2010-2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(3): 141-148.
[13]	黑龙江省医学会乳腺肿瘤学组. 黑龙江省乳腺癌HER2低表达临床病理诊断专家共识(2024版)[J]. 实用肿瘤学杂志, 2024, 38(2): 71-78.
[14]	孟凡岗, 陈飞, 甄立军. DLX2对乳腺癌细胞增殖、迁移、侵袭、凋亡及乳腺癌干细胞特性的影响[J]. 实用肿瘤学杂志, 2024, 38(2): 88-95.
[15]	郑鹏飞, 董良鹏, 高延鑫, 张一夫, 秦双. 白细胞介素-38对乳腺癌患者CD8⁺T淋巴细胞功能的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 30-36.